Literature DB >> 10355656

Predictable recovery from myasthenia gravis crisis with plasma exchange: thirty-six cases and review of current management.

K Mahalati1, R B Dawson, J O Collins, R F Mayer.   

Abstract

Adult, acquired, idiopathic, autoimmune myasthenia gravis has a well-characterized IgG anti-acetylcholine striated-muscle receptor antibody. Removal by plasma exchange is effective, established therapy to augment anti-cholinesterase and immunosuppressive therapy and is the treatment of choice for myasthenia gravis crisis. We report 36 consecutive patients referred and accepted for plasma exchange, 32 of whom were in or entering myasthenia crisis, over a 10 year period. An average of 7.8 (range 1 to 16) plasma exchange procedures were done, with uniform, significant improvement, including extubation of 13 in myasthenic crisis and discharge from hospital in all. We conclude that this is the best treatment for myasthenia gravis crisis in hospital. From recent cases, most, if not all, crises can be prevented by IVIgG or plasma exchange as out-patients with use of corticosteroid and or azathioprine.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10355656     DOI: 10.1002/(sici)1098-1101(1999)14:1<1::aid-jca1>3.0.co;2-u

Source DB:  PubMed          Journal:  J Clin Apher        ISSN: 0733-2459            Impact factor:   2.821


  2 in total

1.  Beneficial effects of plasmapheresis before thymectomy on the outcome in myasthenia gravis.

Authors:  Takeshi Nagayasu; Takatomo Yamayoshi; Keitaro Matsumoto; Noboru Ide; Satoshi Hashizume; Masahito Nomura; Masashi Muraoka; Tsutomu Tagawa; Shinji Akamine; Tadayuki Oka
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  2005-01

2.  The effect of secular trends and specialist neurocritical care on mortality for patients with intracerebral haemorrhage, myasthenia gravis and Guillain-Barré syndrome admitted to critical care : an analysis of the Intensive Care National Audit & Research Centre (ICNARC) national United Kingdom database.

Authors:  Maxwell S Damian; Yoav Ben-Shlomo; Robin Howard; Tony Bellotti; David Harrison; Kathryn Griggs; Kathryn Rowan
Journal:  Intensive Care Med       Date:  2013-05-24       Impact factor: 17.440

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.